Sanofi SA Looks Like One Of The Better Bargains In Big Pharma

Sanofi's diverse pipeline is a marked contrast to many Big Pharma peers.

Feb 8, 2014 at 10:00AM

Even with the recent weakness in the market, there is no surfeit of cheap pharma stocks. Maybe it's not so surprising that Sanofi (NYSE:SNY), a company which has taken a different path than most of its Big Pharma peers, stands out as an exception. Sanofi has not concentrated so keenly on the oncology or anti-inflammatory spaces, and the company has a sizable direct presence in many emerging markets.

While Sanofi's guidance for 2014 was both disappointing and short on details, I think these shares are worth consideration. Strong franchises in diabetes, rare diseases, and vaccines generate good cash flow, and a broad pipeline gives the company a more diversified business mix. My growth expectations are higher than for most pharma companies, but I believe the shares ought to trade in the $50's today.

In-Line Results, With Weak Guidance
Sanofi's revenue declined in 1% on a reported basis, but rose more than 6% in local currency. Pharma revenue was up 1% as reported and more than 8% on a currency-adjusted basis, with Lantus (which contributes more than 15% of the company's revenue) up 13%. Genzyme also continues to deliver strong growth, with sales up more than 30% in local currency and double-digit growth across much of the business. Vaccines (flat) and animal health (down 6%) weren't so impressive, while consumer was up more than 6%. 

Margins were mixed, as gross margin was up a bit but below expectations on mix and vaccine manufacturing issues. Operating income was up 17% as reported, though, and basically in line with expectations. Guidance was problematic. Management was light on specifics (and has a reputation for being conservative), but it looks like sales for 2014 are going to be about 10% lower than expected on a reported basis. More than half of that is due to currency, which mitigates the disappointment to some extent, but a 3% to 5% lower number in constant currency is not a positive development.

Holding Market Share In Diabetes
Not unlike Lilly and Novo Nordisk (NYSE:NVO), Sanofi is finding it challenging to really move its diabetes franchise forward in a big way. Pricing on Lantus has been pretty strong, but the data on the new U300 insulin have been more "solid" than "game-changing". That's not as big of a concern as the FDA rejection that Novo Nordisk has had to work through on Tresiba, but it does mitigate some of the growth potential. Likewise, I haven't seen much from Lyxumia (the company's GLP-1 drug) to make me think it's going to redefine the GLP-1 space that Novo basically dominates.

On the Lilly front, Sanofi has filed suit against Lilly over the latter's biosimilar Lantus product. Barring summary judgment against Sanofi, this should stall Lilly by at least 30 months. With that delay, there's a better chance of U300 getting to market and Sanofi switching patients over from Lantus to U300. Lilly also has a stronger portfolio of diabetes medications outside of insulin, with a GLP-1 (dulaglutide), DPP-IV (Tradjenta), and SGLT2 (empagliflozin) drug. Perhaps Sanofi could be interested in Lexicon's unpartnered SGLT1/2 inhibitor, but that opportunity has been available for some time now.

What this all means to me is that the diabetes space is likely to remain more or less as it is – highly lucrative for Lilly, Novo, and Sanofi, but a difficult area in which to really affect real market share growth. Sanofi is likely going to push Lantus pricing higher and look to compete aggressively with Novo in the growing emerging market opportunity in insulin, but Novo and Lilly aren't going to sit around and just cede share or revenue to Sanofi.

Will Diversification Pay Off?
Big Pharma has taken an interesting turn of late, with companies like Bristol-Myers and Merck increasingly winnowing down their research focus. With that, there is a lot of R&D money going into oncology and inflammatory conditions (rheumatoid arthritis, for example). There are over 500 compounds in clinical development for oncology (though the real number is likely closer to 200 due to double-counting) and more than 20 for RA, and though many will fail that is a lot of effort being devoted to a small number of targets. 

Sanofi is definitely staking out a different approach. Sanofi's efforts in oncology haven't gone particularly well, though the company's partnership with Regeneron does include anti-inflammatory targets. Sanofi's pipeline is considerably broader in terms of the therapeutic areas it addresses (including strong efforts in vaccines and rare diseases) and that could pay off down the line in terms of larger market shares and more stable cashflow.

The Bottom Line
The outlook for Sanofi's MS drug Lemtrada is still quite uncertain, but I do believe that the company's PSCK9 cholesterol drug (partnered from Regeneron) and IL-6 rheumatoid arthritis drug could deliver $2 billion in combined revenue by the end of this decade. Coupled with other existing platforms and the pipeline, I believe Sanofi could deliver revenue growth of nearly 4% over the long term, putting it at the high end of Big Pharma and supporting mid-single digit free cash flow growth.

I calculate a fair value of around $55 for Sanofi, but management's weak guidance underlines some of the risks, particularly as the company targets growth in emerging markets. Fierce competition in diabetes (and the possibility of biosimilars) is definitely a threat, but Sanofi looks like one of the better risk-reward opportunities in Big Pharma today.

A stock with even better growth opportunity
Opportunities to get wealthy from a single investment don't come around often, but they do exist, and our chief technology officer believes he's found one. In this free report, Jeremy Phillips shares the single company that he believes could transform not only your portfolio, but your entire life. To learn the identity of this stock for free and see why Jeremy is putting more than $100,000 of his own money into it, all you have to do is click here now.

Stephen D. Simpson, CFA owns shares of Lexicon Pharmaceuticals. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.


Compare Brokers